Certriad FDA Approval Status
FDA Approved: No
Brand name: Certriad
Generic name: rosuvastatin calcium and fenofibric acid
Company: Abbott and AstraZeneca
Treatment for: High Cholesterol, Hypertriglyceridemia, Hyperlipoproteinemia
Certriad (rosuvastatin calcium and fenofibric acid) is a combination of the active ingredients in Crestor and Trilipix intended for the treatment of mixed dyslipidemia.
In March 2010, AstraZeneca and Abbott announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Certriad (rosuvastatin/fenofibric acid delayed release) capsules had not been approved.
Development timeline for Certriad
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.